SCHEMBL4354299

SCHEMBL4354299

CCOc1ccc(F)cc1C(=O)c1cnc(SC)nc1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.45
HTT P42858 2/20 0.45
CDK1 P06493 2/20 0.43
CDK4 P11802 2/20 0.43
CCND1 P24385 2/20 0.43
CDK2 P24941 2/20 0.43
LMNA P02545 3/20 0.43
NPSR1 Q6W5P4 1/20 0.41
SMN1; SMN2 Q16637 9/20 0.40
ALDH1A1 P00352 6/20 0.40
NPC1 O15118 6/20 0.40
RAB9A P51151 6/20 0.40
MAPT P10636 3/20 0.40
HSD17B10 Q99714 2/20 0.40
TSHR P16473 2/20 0.40
NFKB1 P19838 2/20 0.40
NFKB2 Q00653 2/20 0.40
RELA Q04206 2/20 0.40
RECQL P46063 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13621484 0.90 SMN1; SMN2 (0.44) MAPK1HTTCDK1CDK4CCND1
SCHEMBL4361083 0.89 CDK1 (0.53) MAPK1HTTCDK1CDK4CCND1
SCHEMBL4348384 0.85 HTT (0.43) MAPK1HTTCDK1CDK4CCND1
SCHEMBL4355071 0.81 CDK1 (0.42) CDK1CDK4CCND1CDK2SMN1; SMN2
SCHEMBL4352506 0.81 CDK1 (0.51) MAPK1HTTCDK1CDK4CCND1
SCHEMBL4359313 0.80 CDK1 (0.41) HTTCDK1CDK4CCND1CDK2
SCHEMBL4363762 0.79 SMN1; SMN2 (0.44) MAPK1HTTCDK1CDK4CCND1
SCHEMBL4352694 0.76 SMN1; SMN2 (0.53) MAPK1CDK1CDK4CCND1CDK2
SCHEMBL13621485 0.75 SMN1; SMN2 (0.42) MAPK1HTTCDK1CDK4CCND1
SCHEMBL4357734 0.75 SMN1; SMN2 (0.44) MAPK1HTTLMNASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US claimed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US claimed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US claimed
US-7615634-B2 4-aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2009-11-10 US disclosed
US-7157455-B2 4-Aminopyrimidine-5-one derivatives HOFFMANN-LA ROCHE INC. (US) 2007-01-02 US disclosed
US-20060229330-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID J 2006-10-12 US disclosed
EP-1628619-A2 4-AMINOPYRIMIDINE-5-ONE F.HOFFMANN-LA ROCHE AG (CH) 2006-03-01 EP disclosed
US-20040162303-A1 4-aminopyrimidine-5-one derivatives BARTKOVITZ DAVID JOSEPH (US) 2004-08-19 US disclosed
WO-2004069139-A2 4-AMINOPYRIMIDIN-5-YL-METHANONE DERIVATIVES FOR INHIBITION OF CDK4 ACTIVITY F.HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162303-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK6 MAPK1 742/4885HTT 4508/4885CDK1 6/4885
US-20060229330-A1 4-aminopyrimidine-5-one derivatives CDK4, CDKL4, CDK2 MAPK1 581/4885HTT 3941/4885CDK1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.